Take a sneak peek at the new NIST.gov and let us know what you think!
(Please note: some content may not be complete on the beta site.).
NIST Authors in Bold
|Author(s):||Meiyao Wang; Yang Shen; Illarion V. Turko; Daniel Nelson; Shuwei Li;|
|Title:||Determining carbapenemase activity with 18O labeling and targeted mass spectrometry|
|Published:||October 16, 2013|
|Abstract:||Carbapenems are broad spectrum antibiotics considered as last resort drugs to treat bacterial infections. Carbapenem-hydrolyzing β-lactamases (also called carbapenemases), however, can confer bacterial resistance and represent a serious health threat. Here, we report a novel approach using 18O labeling and selected reaction monitoring to detect carbapenemase activity from pathogenic microorganisms in a rapid and quantitative manner. Four model bacterial strains bearing various classes of β-lactamases were tested for their capability to hydrolyze meropenem, a FDA-approved carbapenem drug. We were able to predict the meropenem resistance of these bacteria based upon their carbapenemase activity, suggesting the great potential of our method in clinical diagnostics.|
|Pages:||pp. 11014 - 11019|
|Keywords:||carbapenemase, selected reaction monitoring, isotope labelling, mass spectrometry|
|Research Areas:||Diagnostics, Drugs/Pharmaceuticals, Bioscience & Health|
|DOI:||http://dx.doi.org/10.1021/ac402627k (Note: May link to a non-U.S. Government webpage)|